Analysts Set argenx SE (NASDAQ:ARGX) Target Price at $530.42

argenx SE (NASDAQ:ARGX) has earned an average rating of “Moderate Buy” from the twenty-one ratings firms that are presently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, five have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $530.74.

A number of brokerages have issued reports on ARGX. Truist Financial boosted their price objective on shares of argenx from $370.00 to $440.00 and gave the company a “buy” rating in a research report on Tuesday, March 5th. Piper Sandler boosted their price objective on shares of argenx from $518.00 to $522.00 and gave the company an “overweight” rating in a research report on Friday, January 26th. JMP Securities reaffirmed a “market outperform” rating and issued a $471.00 target price on shares of argenx in a research report on Friday, March 22nd. JPMorgan Chase & Co. reduced their target price on shares of argenx from $615.00 to $560.00 and set an “overweight” rating on the stock in a research report on Tuesday, December 5th. Finally, Scotiabank upped their target price on shares of argenx from $402.00 to $408.00 and gave the stock a “sector perform” rating in a research report on Tuesday.

Hedge Funds Weigh In On argenx

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Parkside Financial Bank & Trust bought a new position in argenx during the 3rd quarter valued at about $28,000. ADAR1 Capital Management LLC bought a new position in shares of argenx in the 4th quarter worth approximately $27,000. KB Financial Partners LLC lifted its stake in shares of argenx by 112.5% in the 1st quarter. KB Financial Partners LLC now owns 85 shares of the company’s stock worth $27,000 after purchasing an additional 45 shares during the period. FNY Investment Advisers LLC bought a new position in shares of argenx in the 4th quarter worth approximately $38,000. Finally, Nkcfo LLC lifted its stake in shares of argenx by 22.1% in the 3rd quarter. Nkcfo LLC now owns 116 shares of the company’s stock worth $57,000 after purchasing an additional 21 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenx Price Performance

Shares of argenx stock opened at $398.59 on Friday. argenx has a 1 year low of $327.73 and a 1 year high of $550.76. The firm has a market cap of $23.64 billion, a PE ratio of -77.55 and a beta of 0.65. The company has a 50 day simple moving average of $387.39 and a two-hundred day simple moving average of $435.23.

argenx (NASDAQ:ARGX) last announced its quarterly earnings data on Thursday, February 29th. The company reported ($1.68) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.23) by ($0.45). The business had revenue of $417.84 million during the quarter, compared to the consensus estimate of $378.60 million. argenx had a negative return on equity of 16.97% and a negative net margin of 23.26%. During the same quarter in the previous year, the firm posted ($0.70) earnings per share. As a group, research analysts anticipate that argenx will post -2.07 earnings per share for the current year.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.